Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.
Jane Lee, PharmD, BCPS, BCOP
Advertisement
Articles by Jane Lee, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Addition of Tremelimumab-actl to Durvalumab-Based Regimen May Broaden Clinical Activity in uHCC, mNSCLCPublished: February 15th 2023 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
5
